Adoptive FAP-specific chimeric antigen receptor (CAR) T-cell therapy is an innovative approach to directly target and deplete most FAP+ CAFs and to restrict tumor stroma production, resulting in antitumor effects [90]. Here, FAP is linked to neoplasm.